索引于
- 学术期刊数据库
- 打开 J 门
- Genamics 期刊搜索
- 学术钥匙
- 期刊目录
- 中国知网（CNKI）
- 引用因子
- 西马戈
- 乌尔里希的期刊目录
- 电子期刊图书馆
- 参考搜索
- 哈姆达大学
- 亚利桑那州EBSCO
- OCLC-WorldCat
- SWB 在线目录
- 虚拟生物学图书馆 (vifabio)
- 普布隆斯
- 米亚尔
- 大学教育资助委员会
- 日内瓦医学教育与研究基金会
- 欧洲酒吧
- 谷歌学术
分享此页面
期刊传单
抽象的
Assessment of Bioequivalence between the Higher Strengths of Pirfenidone 400 mg and 600 mg with Equivalent Doses of Pirfenidone 200 mg
Hemant Joshi, Mukesh Kumar, Jaideep Gogtay, Meena Lopez, Milind Gole, Richa Sharma
Background: The standard of care for idiopathic pulmonary fibrosis is pirfenidone 200 mg tablets thrice daily (t.i.d, 600 mg/day) which is titrated to achieve the desired maintenance dose i.e 1800-2400 mg/day (600 mg-800 mg, t.i.d). However, this is associated with a high pill burden and can impact patient compliance. Therefore, two higher strengths (400 mg and 600 mg) of pirfenidone tablets have been developed which offer greater flexibility to facilitate tailored dosing and likely to improve patient compliance.
Methods: Two studies were conducted using an open-label, randomized, single-dose, two-treatment, two-period, twosequence, two-way crossover design in fed conditions with a washout period of 5-6 days between administration. In the first study, a single dose of 400 mg pirfenidone tablet was compared with 2 × 200 mg pirfenidone tablets and in the second study a single dose of 600 mg pirfenidone tablet was compared with 3 × 200 pirfenidone tablets. The assessment of bioequivalence between treatments in study 1: pirfenidone 1 × 400 mg vs. 2 × 200 mg tablets and study 2: pirfenidone 1 × 600 mg vs. 3 × 200 mg tablets was done by comparing the pharmacokinetic parameters: Cmax, AUC0-t and AUC0-∞.
Results: 17 subjects were evaluated in the study with the lower strength (400 mg) and 43 subjects were evaluated in the study with the higher strength (600 mg). The ratios and 90% CI for the geometric mean in study 1 were 102.90% (89.33%-115.97%) for Cmax, 104.61% (92.74%-116.58%) for AUC0-t and 107.94% (95.75%-120.75%) for AUC0-∞. The ratios and 90% CI for the geometric mean in study 2 were 97.96% (91.41%-104.99%) for Cmax, 97.79% (93.96%-101.78%) for AUC0-t and 97.88% (94.10%-101.81%) for AUC0-∞. One adverse event was reported in study 1 and 4 adverse events in study 2. None of the adverse events were deemed to be serious AEs. All the treatments were well tolerated.
Conclusion: Single doses of pirfenidone 400 mg tablets when compared with pirfenidone 2 × 200 mg tablets and pirfenidone 600 mg tablets when compared with the 3 × 200 mg tablets met the bioequivalence criteria in terms of rate and extent of absorption under fed condition.